Background: Geographical miss (GM), representing suboptimal drug-eluting stent deployment, is associated with an increased risk of target lesion revascularization (TLR) and myocardial infarction. The impact of suboptimal stenting techniques on clinical outcomes in diabetics remains unknown.
linical outcomes after percutaneous coronary intervention are influenced by clinical and anatomical factors. Diabetes mellitus remains an important risk factor in patients with coronary artery disease treated with drug-eluting stents. 1- 4 The impact of stent deployment techniques on clinical outcomes of patients treated with sirolimus-eluting stents (SES) was recently investigated in the Stent deployment Techniques on cLinicaL outcomes of patients treated with the cypheR TM stent (STLLR) trial. 5 Geographical miss (GM) was associated with a higher incidence of target vessel revascularization (TVR) and myocardial infarction 1 year after the deployment of SES. The term GM was first introduced in interventional cardiology when describing the failure to fully treat the diseased coronary artery segment and was also recognized as an important predictor of restenosis after brachytherapy. 6,7 However, it is unknown how procedural factors, such as GM, influence the outcomes in diabetics, a subpopulation at increased risk of acute and longterm cardiovascular complications. 1-3,8, 9 The aim of the present study is to evaluate how GM during deployment of SES impacts the outcomes of a diabetic population.
Methods
STLLR is a prospective, multicenter study conducted in 41 US centers that enrolled 1,557 consecutive patients to evaluate clinical outcomes associated with SES deployment techniques in real-world practices (ClinicalTrials.gov identifier: NCT00403338). A detailed description of the protocol has been previously reported. 5 In summary, within 72 h after implantation of SES, cineangiograms were transmitted to an independent angiographic core laboratory, which analyzed all the steps of the percutaneous coronary intervention proce-TAHARA S et al.
dures at the time of study entry to determine the occurrence of GM. All patients were allocated into the GM group or non-GM group. Investigators and patients remained blind to the group assignments throughout the study. Eligible patients had a clinical diagnosis of stable angina pectoris, as defined by the Canadian Cardiovascular Society Classification, unstable angina pectoris class B, C, and I-II defined using the Braunwald classification, or documented silent ischemia. Study inclusion criteria was the presence of de novo stenosis of a major coronary artery, with target lesion >50% and <100% stenosis that could be treated with commercially available SES. Patients were not considered candidates for the study if they had ST-elevation myocardial infarctions within 24 h of the procedure, target vessels previously treated with radiation therapy, unprotected left main disease, stenosis located in saphenous veins or arterial bypass grafts, documented left ventricular ejection fraction <25%, severely impaired renal function (creatinine >3.0 mg/dl), or a history of heart transplantation. Patients with a life expectancy <12 months or those already participating in another investigational drug or device study were excluded from the study. All patients had to provide written informed consent before the procedure.
GM was defined angiographically into 2 categories: longitudinal GM (LGM) and axial GM.
LGM was determined in cases in which the entire length of the diseased or injured segment was not fully covered by the total length of SES. Furthermore, LGM was subcategorized into 3 types: balloon injury, uncovered disease, or both. Axial GM was defined in cases in which the ratio between the size of the largest balloon (at its maximum inflation pressure) and the reference vessel diameters was ≤0.9 or ≥1.3.
Operators were instructed to select a stent length to cover the entire stenotic segment, including the entire segment injured by balloon inflation. Stent length was recommended to be at least 6 mm longer than the estimated lesion length, providing a proximal and distal landing zone free of angiographic narrowing. If predilation was performed, stent length was recommended to be at least 5 mm longer than the extent of the balloon injury segment in cases of multiple inflations or the balloon length if a single inflation was performed. Angiography was performed to document every step of the procedure, including balloon and stent positioning and inflations. The procedure goal was to achieve residual diameter stenosis <20% and Thrombolysis In Myocardial Infarction 3 flow. Interpolated reference diameter and minimal lumen diameter were calculated in 2 orthogonal angiographic views using an automated contour detection algorithm (CAAS II; Pie Medical BV, Maastricht, The Netherlands). 10 Clinical follow-ups were scheduled at 1, 6, or 12 months after the procedure, and all adverse events were adjudicated independently by a clinical events committee also blinded to the angiographic GM assignments. The primary endpoint was the incidence of target lesion revascularization (TLR) 12 months after the procedure. TLR was defined as any repeated percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for a clinical indication and caused by restenosis or closure of the target lesion. Secondary clinical endpoints included incidences of GM, TVR, and the safety endpoints of myocardial infarction, stent thrombosis, and death. TVR was defined as any repeated percutaneous intervention or bypass surgery of the target vessel. Qwave myocardial infarction was defined as the development of new pathologic Q waves in ≥2 contiguous leads with postprocedure creatinine kinase or myocardial-bound creatinine kinase (CK-MB) higher than normal. Non-Q-wave myocardial infarction was defined by increased creatinine kinase to >2 times normal with increased CK-MB in the absence of new pathologic Q-waves. Subacute thrombosis was defined as a 
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composite 30-day ischemic endpoint, including death, Q-wave myocardial infarction, or abrupt closure requiring revascularization. Any death not attributable to a non-cardiac cause in the first 30 days or any Q-wave myocardial infarction in the territory of the target vessel in the first 30 days was considered a surrogate for stent thrombosis if vessel patency was not documented using angiography. Late stent thrombosis was defined as myocardial infarction occurring >30 days after the index procedure and attributable to the target vessel with angiographic documentation of thrombus or total occlusion at the target site and freedom from interim TVR. Both subacute and acute thromboses were included into thrombosis. The presence of diabetes mellitus was determined by documentation through self-reporting by the patient and when a patient's %HbA1c was ≥6.5% for patients who had no history of diabetes. All diabetics were included regardless of the type of diabetes treatment (diet only, insulin, or oral antidiabetic agents).
Statistical Analysis
All analyses were conducted with SAS, version 8.2 (SAS Institute, Cary, NC, USA). A value of P<0.05 was considered significant. Continuous variables were expressed as mean ± SD, and categorical variables were expressed as frequencies. The P-values were calculated using a t-test if the variable was continuous. Chi-square test or Fisher's extract test was used if the variable was categorical. Predictors of TLR were identified using univariate and multivariate logistic regression models containing factors demonstrated on univariate analysis to predict the frequency of the TLR and factors previously associated with the event outcome in the literature. The odds ratio (OR) with a 95% confidence interval (CI) was calculated for the determination of the significance of the value.
Results
A total of 1,557 patients treated with SES were enrolled, of whom assessment of both LGM and axial GM was possible in 1,419 patients (91.1%). In the remaining patients, assessment of GM was impossible due to inadequate angiography for core lab standards. Among 1,419 patients, it was possible to accurately determine the presence or absence of diabetes in 1,336 patients. Overall, diabetes was present in 28.8% of patients (n=385). Baseline clinical characteristics of diabetic and nondiabetic patients enrolled in STLLR are shown in Table 1 . A higher incidence of obesity, hypertension, and dyslipidemia were observed in diabetics, but smoking was less frequent in diabetics. Similar differences were also observed in both the LGM and non-LGM populations.
Baseline lesion and procedural characteristics are shown in LGM, longitudinal geographic miss. Other abbreviations see in Tables 1,3 . Tables 3,4 . Acute Gain as a Predictor of TLR After SES 
non-diabetics (P=NS). For bifurcations, the single stent technique was used in all diabetics and in the vast majority of non-diabetics (93.8%, P=NS).
Somewhat expected, minimal lumen diameter, reference diameter, and acute gains were smaller in diabetics compared to non-diabetics. Diffuse disease was more frequent in diabetics (27.0%) compared to non-diabetics (20.9%), but target lesion lengths were similar between the 2 groups. Table 3 shows 1-year clinical outcomes separating diabetics and nondiabetics. Overall, there was a trend towards higher rates of TLR in the diabetic population (4.7% vs. non-diabetics 2.8%, P=0.09), which was similar across other endpoints.
LGM occurred in 180/385 diabetics (46.7%), while axial GM occurred in 64/205 (31.2%). The frequency of each GM was similar with non-diabetics (LGM 47.5%, axial GM 24.0%). The original anatomy of TLR vessels was similar in both diabetics and non-diabetics As shown in Table 4 , when LGM occurred, it was associated with a 4.1 times increase in the rate of TLR among diabetics (P=0.007). Non-diabetics with LGM also experienced an increase in TLR rates, although to a lesser degree (1.9 times, P=0.10). However, TLR was similarly low in diabetics and non-diabetics treated with the optimal technique, ie, in the non-LGM subpopulation.
The incidence of each type of LGM was similar between diabetics and non-diabetics (balloon injury: 45.5% vs. 47.6%, uncovered disease: 30.6% vs. 32.1%, both: 23.9% vs. 20.4%, 
Discussion
The present study demonstrated that lesser acute gain is the exclusive predictor of TLR of SES independent of the presence of LGM or diabetes. Diabetes mellitus seemed to amplify the unfavorable clinical consequences of LGM during SES deployment. However, the finding that optimal SES techniques might offer diabetics low TLR rates that are similar to that of the non-diabetic population was reassuring. The study also revealed that LGM affects non-diabetics as well, but in a slightly different manner. Uncovered disease was associated with higher rates of repeat revascularization in both diabetic and non-diabetic subpopulations, but balloon injury had a worse impact on diabetic patients.
The STLLR trial has demonstrated the negative impact of the suboptimal technique during percutaneous coronary intervention on long-term clinical outcomes in general population patients treated with SES coronary implantations. 5 This study highlighted that technical factors related to percutaneous coronary intervention and stent placement remain an important determinant of clinical outcomes in spite of the strong antiproliferative properties of SES. In the present study, using multivariate analysis, acute gain turned out to be the only independent predictor of TLR after SES. This finding reminds us that adequate stent expansion remains a fundamental technical issue that we have to resolve in the use of DES, despite the expected lower late lumen loss with DES compared to BMS. Postdilation with appropriate balloon sizes using much higher pressures could help us to acquire larger acute gain to lower the TLR rate.
The present data provides further insights into the impact of procedural factors in a specific high-risk patient subgroup with diabetes mellitus. Diabetes mellitus has been recognized as a strong predisposing factor influencing restenosis and overall outcomes after stent implantation. 11 Implantations with bare metal stents did not improve clinical events in the subset of diabetic patients because of a higher incidence of in-stent restenosis. 12-15 Drug-eluting stents have accomplished improvements in the long-term safety outcomes in diabetic patients when compared with bare metal stents. [16] [17] [18] [19] Nevertheless, diabetics are still more susceptible to higher TLR rates compared to non-diabetics. 1-4, 20 Our study corroborated these previous findings, but showed that the overall occurrence of restenosis manifested clinically as TLR in diabetics was comparable to that observed in non-diabetics, when treated with optimally deployed SES. However, sub-optimally treated diabetics experienced a rate of TLR that was 4 times higher than diabetics without LGM. Taken together, these results further stress the need for judicious techniques when performing percutaneous coronary interventions in patients with diabetes.
Stent edge plaque burden has been shown to be a strong peri-procedural predictor of restenosis after bare metal stents and SES. 5,21, 22 Our study suggests that uncovered disease affects both diabetics and non-diabetics equally with TLR rates (7.3% vs. 7.6%). This observation suggests that the growth of the plaque burden at stent edges is not affected by the existence of diabetes and might be influenced by other factors. Subsequent vessel negative remodeling after SES stenting might also contribute to the observed increase of TLR. 23 On the contrary, the contribution of balloon injury to higher TLR rates was exclusively observed in diabetics. The present findings might be explained by local inflammatory responses induced by balloon injury and further exacerbated by hyperinsulinemia. Although such a hypothesis would require a specific study of insulin levels, preclinical studies using diabetic animal models support the notion that hyperinsulinemia contributes to accelerated neointimal growth after balloon injury. 24,25 However, in patients without diabetes, the less intense inflammatory and proliferative response to balloon injury might be insufficient to offset the acute lumen gain offered by the balloon angioplasty. These results, although intriguing, should be interpreted with caution, as residual disease severity and the intensity of balloon angioplasty might have influenced our findings. Thus, a strategy of routine angioplasty of residual angiographic disease post-SES deployment in non-diabetic patients cannot be recommended at this point. Given that information, a large prospective study would be required to determine which strategy is best: balloon angioplasty, additional drug-eluting stents, or no additional intervention to treat mild-moderate residual stenosis after deployment of drug-eluting stents.
Although the main purpose of the STLLR trial was to assess the impact of the GM in angio-guided percutaneous coronary intervention, it is possible that the use of additional imaging modalities, such as intravascular ultrasound and optical coherence tomography, could improve our ability to optimally assess and treat patients with coronary disease, particularly to achieve larger acute gain.
Study Limitations
The present report is a sub-analysis of the STLLR trial and subject to the usual inherent biases of post-hoc analyses. However, a prospective randomized trial design is likely unattainable, because mandatory assignment of patients to suboptimal percutaneous coronary intervention would be unethical. This study did not monitor compliance with anti-diabetic therapy and lacked precise data on the control of glucose and insulin levels that might also have had an impact on outcomes for all diabetic patients. Although, to the best of our knowledge, this is the largest trial assessing GM by an independent core lab in a diabetic population, the low events per variable
